VC: Therion raises $30 million



Therion raises $30 million in fourth round.

VENTURE CAPITAL

COMPANY

AMOUNT/ROUND

LEAD INVESTORS

DESCRIPTION

Therion Biologics
Cambridge, MA

$30M
fourth

Hans-Werner Hector

The funds will go to the clinical development of PanVac-VF and ProstVaC-VF, its lead product candidates to treat pancreatic cancer and prostate cancer.

ProMetic Life Sciences
Montreal

$15M
undisclosed

Sprott Securities

ProMetic has been developing treatments for cancer and inflammation/autoimmune diseases.

Exagen Diagnostics
Albuquerque, NM

$7M
second

Tullis-Dickerson & Co

Exagen is developing genomic market IVD kits for breast cancer.

AmpliMed Corp
Tucson, AZ

$5M
two

Biotech Insight Ventures

The money will go to expand its pipeline of cancer drugs and push new clinical trials.

TriMed Research
Omaha, NE

$5M
one

Inventages venture capital investments

TriMed is beginning to develop therapies based on research related to the mammary gland protein designated as MAA.

Suggested Articles

Californian RNA biotech Arrowhead will lose its COO and R&D head from next year but is hiring a new CMO and CSO to help steady its research exec team.

The biotech began testing the small molecule in a phase 3 trial of heavily pretreated small cell lung cancer patients late last year. 

Roche is spending up to $1.4 billion to snap up a scarring-focused biotech, nabbing an FDA breakthrough-tagged therapy in the process.